RNA-loaded nanoparticles for the treatment of hematological cancers

IF 15.2 1区医学 Q1 PHARMACOLOGY & PHARMACY Advanced drug delivery reviews Pub Date : 2024-09-18 DOI:10.1016/j.addr.2024.115448

Elisa Garbayo , Souhaila H. El Moukhtari , Carlos Rodríguez-Nogales , Xabier Agirre , Juan R. Rodriguez-Madoz , Paula Rodriguez-Marquez , Felipe Prósper , Patrick Couvreur , María J. Blanco-Prieto

{"title":"RNA-loaded nanoparticles for the treatment of hematological cancers","authors":"Elisa Garbayo , Souhaila H. El Moukhtari , Carlos Rodríguez-Nogales , Xabier Agirre , Juan R. Rodriguez-Madoz , Paula Rodriguez-Marquez , Felipe Prósper , Patrick Couvreur , María J. Blanco-Prieto","doi":"10.1016/j.addr.2024.115448","DOIUrl":null,"url":null,"abstract":"<div><p>Hematological cancers encompass a diverse group of malignancies affecting the blood, bone marrow, lymph nodes, and spleen. These disorders present unique challenges due to their complex etiology and varied clinical manifestations. Despite significant advancements in understanding and treating hematological malignancies, innovative therapeutic approaches are continually sought to enhance patient outcomes.</p><p>This review highlights the application of RNA nanoparticles (RNA-NPs) in the treatment of hematological cancers. We delve into detailed discussions on <em>in vitro</em> and preclinical studies involving RNA-NPs for adult patients, as well as the application of RNA-NPs in pediatric hematological cancer. The review also addresses ongoing clinical trials involving RNA-NPs and explores the emerging field of CAR-T therapy engineered by RNA-NPs. Finally, we discuss the challenges still faced in translating RNA-NP research to clinics.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"214 ","pages":"Article 115448"},"PeriodicalIF":15.2000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24002709/pdfft?md5=394e09e402e81b0f66099b1b06ffb9f2&pid=1-s2.0-S0169409X24002709-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced drug delivery reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169409X24002709","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Hematological cancers encompass a diverse group of malignancies affecting the blood, bone marrow, lymph nodes, and spleen. These disorders present unique challenges due to their complex etiology and varied clinical manifestations. Despite significant advancements in understanding and treating hematological malignancies, innovative therapeutic approaches are continually sought to enhance patient outcomes.

This review highlights the application of RNA nanoparticles (RNA-NPs) in the treatment of hematological cancers. We delve into detailed discussions on in vitro and preclinical studies involving RNA-NPs for adult patients, as well as the application of RNA-NPs in pediatric hematological cancer. The review also addresses ongoing clinical trials involving RNA-NPs and explores the emerging field of CAR-T therapy engineered by RNA-NPs. Finally, we discuss the challenges still faced in translating RNA-NP research to clinics.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于治疗血液肿瘤的 RNA 载体纳米粒子

血液肿瘤包括影响血液、骨髓、淋巴结和脾脏的各种恶性肿瘤。由于病因复杂、临床表现各异，这些疾病带来了独特的挑战。尽管在了解和治疗血液恶性肿瘤方面取得了重大进展，但人们仍在不断寻求创新的治疗方法来改善患者的预后。本综述重点介绍了 RNA 纳米粒子（RNA-NPs）在血液癌症治疗中的应用。我们详细讨论了针对成人患者的 RNA-NPs 体外和临床前研究，以及 RNA-NPs 在儿童血液肿瘤中的应用。综述还讨论了正在进行的涉及 RNA-NPs 的临床试验，并探讨了由 RNA-NPs 改造的 CAR-T 疗法这一新兴领域。最后，我们讨论了在将 RNA-NP 研究成果转化为临床治疗方面仍然面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advanced drug delivery reviews 医学-药学

CiteScore

28.10

自引率

5.00%

发文量

294

审稿时长

15.1 weeks

期刊介绍： The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery. In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.